Study #2023-0459
A phase 2, open-label, multi-arm study of tislelizumab in combination with investigational agents with or without chemotherapy in patients with previously untreated, locally advanced, unresectable, or metastatic non-small cell lung cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Tislelizumab, BGB-A445, LBL-007, BGB-15025, Carboplatin, Cisplatin, pemetrexed, Paclitaxel, Nab paclitaxel
Description
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Study phase:
Phase II
Physician name:
George Blumenschein
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.